All News

Amelie G. Ramirez, DrPH, MPH, director of the Institute for Health Promotion Research at UT Health Science Center San Antonio, discussed the need for standardized questionnaires for clinicians to discuss social determinants of health with their oncology patients.

The discussion delves into the results and implications of the clinical trials, shedding light on the efficacy and safety profile of this combination therapy.

Improvements in PFS were also seen among patients with brain metastases.

pCR rates were improved with the addition of pembrolizumab regardless of whether patients received the full chemotherapy doses.

MONARCH 3 final OS data show that the combination of abemaciclib and a NSAI in the first-line resulted in numerically longer OS compared to an NSAI alone.

Individuals with HR+ breast cancer could pause endocrine therapy for up to 2 years to become pregnant, without increasing the risk of recurrence.

Patients with an estrogen receptor measure greater than 8% and those with little to no TIL expression showed no benefit with the addition of nivolumab.

Carly Giavatto, PharmD, discusses the CPS conducted study that highlights a first of its kind linkage to care initiative performed by health systems specialty pharmacists.

All fills are not equal in their complexity and cost.

Biologic rationale, biomarker precision, and efficacy results in the biomarker-negative population all helped FDA officials decide the final indication.

During clinical trials, individuals treated with iptacopan had increased hemoglobin levels and did not need to receive blood transfusions.

Evidence has shown that reversing pro-cancer effects requires significant weight loss as well as substantial metabolic reprogramming.

Patients with breast cancer who underwent chemotherapy and skipped RNI did not face an increased risk of disease recurrence or death 5 years post-surgery.

Although PFS was improved in patients with unresectable locally advanced or metastatic HER2-positive breast cancer, OS data were immature, requiring further research.

Mridula George discusses the role of personalized circulating tumor DNA monitoring in predicting the response to neoadjuvant therapy for early-stage breast cancer.

Patients enrolled in the study had substantial absolute risks and elevated relative risks, suggesting that AKs may be a clinical marker of UV exposure and increased skin cancer risk.

Trastuzumab deruxtecan and elacestrant both represent important new treatment options for subgroups of patients with breast cancer.

In the first-line setting, inavolisib plus palbociclib and fulvestrant improved PFS in patients with HR-positive breast cancers; however, further research is needed to understand the trends in OS.

The approval marks levothyroxine sodium as the only FDA-granted LT4 therapy that does not have a labeled interaction with PPIs and can be taken 15 minutes prior to eating breakfast.

These patients have slow brain wave activity during wakefulness, which can reduce the firing of nerve cells to protect against the pathology of epilepsy.

Chia seeds are a nutrient dense product that are rich in fiber and omega-3 fatty acids, and could have a hypocholesterolemic effect when ingested.

The study authors note that increasing education, implementing online services, and removing stigma can help improve the uptake of PrEP in this population.

Peter J. Siavelis, discusses the role of the InteLogix platform to enable a more rapid response to changes in the pharmaceutical supply chain.

Currently, there is no established standard of care treatment approach of HGBL, with frontline interventions consisting of chemo-immunotherapies.

Investigators found that positive antiphospholipid antibodies and traditional risk factors were associated with atherosclerotic cardiovascular disease.

Pharmacy Times will be covering the 2023 San Antonio Breast Cancer Symposium (SABCS), happening December 5 through 9 in Texas.

Jennifer N. Clements PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP discusses the role of Semaglutide and Tirzepatide for type 2 diabetes and obesity

A new hydrogel drug delivery system could change the way diabetes is managed.